Robert Bradway

“Amgen delivered another strong quarter, driven by rising demand for our medicines and meaningful progress across the pipeline. Volume growth once again paced our progress in an environment where selling prices are declining across the industry.”

“As you'll hear, Amgen delivered another strong quarter, driven by growing demand for our medicines across the board. With net selling prices for medicines declining across the industry, volume growth is a key differentiator.”

“Bemarituzumab is our first-in-class fibroblast growth factor receptor IIb directed monoclonal antibody. This is a protein that appears on the surface of malignant gastric cancer cells with some frequency.”

“2024 capped another year of strong execution at Amgen. Our operations teams supplied every patient every time. Our clinical teams reliably delivered quality results across the portfolio, and our commercial teams grew the business across our four therapeutic areas and in each of our geographic regions.”

“Our performance this quarter reflects the strength of our business across our core therapeutic areas and geographies. Our in-market medicines performed well in the quarter with third-quarter revenues up 23% to $8.5 billion and 10 of our products delivering double-digit or better sales growth.”